When antacids are administered with other drugs, they can alter the absorption, bioavailability, and/or excretion of concomitantly administered drugs. This study aims to characterize the in vitro interaction between different formulations of mebeverine HCl and magnesium trisilicate antacids and salts used for electrolyte-replacement therapy. The dissolution profiles of different formulations of mebeverine alone and in the presence of aluminium/magnesiumcontaining antacids and salts were studied. The release profiles of the drugs and the model and mechanisms of drug release were determined using differential scanning calorimetry and infrared techniques. The loss of mebeverine HCl in each case appeared to be caused by absorption. The calorimetry and infrared results suggest that mebeverine HCl interacts with the antacids and with Movicol. These results should be added to the in vitro drug-drug interaction chart. It is advisable to administer other drugs at least 0.5-1.0 h before antacid ingestion to ensure consistent absorption and effect and to avoid potential interactions.
INTRODUCTION

I
rritable bowel syndrome might be associated with gastric and duodenal ulcers and inflammation of the gastrointestinal tract (1, 2) . Antacids are the most widely recommended drugs for treatment of the gastrointestinal tract (3) . Antacids are often coadministered with other drugs, including mebeverine HCl, an effective spasmolytic drug with direct action on the smooth muscle of the gastrointestinal tract (4) . Patients suffering from irritable bowel syndrome often complain of constipation, which is usually treated by polyethylene glycol 3350 plus electrolytes (5) . Although the efficacy of many drugs may not be affected by concomitant administration with antacids, many studies of clinically important interactions between antacids and other drugs have shown that antacids reduce the dissolution, inhibit the absorption, and reduce the efficacy of some drugs including tetracyclines, digoxin, phenytoin, and certain psychotherapeutic agents (6) .
Aluminium hydroxide was found to delay gastric emptying and absorption and to lower the blood levels of some drugs (6) . Antacids were found to cause the accelerated excretion of acidic drugs like salicylate and, per contra, might cause the retention of basic drugs like quinidine or amphetamine by elevating the urine pH (6) . In addition, antacid fexofenadine interaction has been shown and revealed significant affinity to form charge transfer complexes as determined by both ultraviolet (UV) spectrophotometry and high-performance liquid chromatography (HPLC) (7) .
A case report study demonstrated treatment failure for supraventricular tachycardia in newborns as a result of interaction among anti-arrhythmia (amiodarone), esomeprazole, and calcium carbonate/sodium bicarbonate/sodium alginate antacid (Gaviscon) (8) . Al 3+-and Mg 2+-containing antacids were found to markedly decrease the absorption of nemonoxacin in healthy
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Chinese males (9) . Another study indicated that there was unfavorable pharmacological interaction between low doses of magnesia laxative and antacid in cancer patients (10) . A recent study revealed that the use of antacids shortened overall survival duration in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients treated with first-line, first-generation EGFR tyrosine kinase inhibitors (TKIs), especially in patients with de novo brain metastasis (11) . Moreover, an in vitro study showed significant adsorption of zidovudine by the antacids, which is thought to reduce the amount of active ingredient available for absorption and subsequently drug resistance and therapeutic failure (12) (13) (14) .
In vivo drug interaction can be potentially predicted by several in vitro techniques, including dissolution. In addition, in vitro studies can be used as a screening tool for further in vivo assessment and can provide the basis for design of subsequent in vivo drug interaction studies.
Since antacids have the capacity to adsorb many drugs, it was warranted to investigate such interaction between several dosage forms of mebeverine HCl and aluminum/ magnesium-containing antacids (15) . Additionally, interaction with electrolyte-replacement therapy was conducted. This issue was studied using different techniques such as in vitro dissolution test, differential scanning calorimetry, and infrared spectrophotometry.
METHODS AND MATERIALS
Materials
Mebeverine 
Dissolution Tests
In vitro release studies of the different formulations of mebeverine HCl were performed at 100 rpm and 37 °C using a USP dissolution apparatus-I (Pharma Test DT 70, Germany). The dissolution medium for the tablets was 900 mL 0.1 M HCl with or without different concentrations of antacid and with or without Movicol salt (1 sachet). Aliquots were withdrawn periodically every 8 min over a 2 h period, appropriately diluted, and measured spectrophotometrically at 264 nm. For the retard capsules, the test was performed in 900 mL 0.1 M HCl for the first 2 h, after which the dissolution medium was adjusted with a known amount of sodium hydroxide to pH 6.8, and samples were withdrawn every 20 min over a period of 3 h, then the amount of drug released was determined.
Differential Scanning Calorimetry Determinations
Differential scanning calorimetry (DSC) thermograms were recorded on an Auto Q20 DSC (TA Instruments, USA) calibrated with indium (99.9%). An aliquot (2 mg) of the sample was heated at a rate of 10 °C/min over a temperature range of 30-350 °C in closed aluminum pans under an argon purge. At least three determinations were used to calculate the mean value and standard deviation for each sample.
Infrared Spectroscopy Determinations
Infrared (IR) spectra were taken from potassium bromide (KBr) pellets on a Nicolet 6700 FT-IR (Thermo Scientific, USA). For the samples, the KBr ratio was 1:300 mg, and a pressure of 15 tons was used. The spectrum was scanned at a resolution of 2 cm -² over a frequency range of 400-4000 cm -¹ with a scan speed of 300 cm
RESULTS AND DISCUSSION
The present study focused on the possibility of interaction between mebeverine HCl and antacids or salts when those compounds are concomitantly administered orally, either as prescribed by a physician or as over-the-counter drugs. The dissolution of different formulations of mebeverine HCl alone and in the presence of different formulations of aluminum/magnesium-containing antacids and salts was studied. The release profiles of the drugs and the model and mechanisms of drug release were determined using dissolution tests. In addition, the mechanisms of interaction between different formulations of mebeverine HCl and magnesium trisilicate antacids and salts used for electrolyte-replacement therapy were characterized based on DSC analysis and IR spectroscopy.
Dissolution Studies
As shown in Figure 1 , it is not recommended to co- Figure 3) . Also, the combination of Duspatalin with 15 mL Rialox suspension in combination with one sachet of Movicol resulted in a weak interaction, as there was a decrease of about 16.8% in the release of mebeverine HCl. The co-administration of Duspatalin with 15 mL Rialox suspension did not result in any significant interactions, as the release of mebeverine HCl was 91.36%; therefore, it would be acceptable to administer those drugs together.
It is not recommended to co-administer Duspatalin with three tablets of Moxal alone or in combination with one sachet of Movicol or with 15 mL Moxal suspension alone, because those combinations resulted in a decrease in the release of mebeverine HCl of 27.7%, 42%, and 15.34%, respectively ( Figure 3) . Also, the combination of Duspatalin with 15 mL Moxal suspension alone or in combination with one sachet of Movicol resulted in weak interactions, as there was a decrease of 15.34% and 25%, respectively, in the release of mebeverine HCl .
The in vitro release studies of Duspatalin with Rialox and Movicol showed that the zero-order model, in which the drug release rate is independent of the concentration of the dissolved substance, produced the highest R 2 value (Table 1) . On the other hand, in vitro release studies of Duspatalin with Moxal and Movicol showed that the Higuchi model produced the highest R 2 value (Table 1) . The highest K values were exhibited when Duspatalin was alone or in the presence of Movicol during dissolution. Duspatalin alone or mixed with an antacid or Movicol had n values less than 0.45, indicating that the drug release follows Fickian diffusion (Table 1) . 
Differential Scanning Calorimetry Analysis
The DSC data are presented in Figure 4 . The curve for pure mebeverine HCl showed a sharp endothermic response corresponding to the melting of the mebeverine HCl at 133 °C. The DSC thermograms of mebeverine HCl 
Infrared Spectroscopy Determinations
The IR spectra are shown in Figure 5 . The spectrum of mebeverine HCl displayed characteristic bands at 2945, 1717, 1265, and 1221 cm -1 assigned to νCH (aliphatic), νC=O (ester), and νC-O (ether; for the last two peaks), respectively. The spectra of mebeverine HCl combined with Rialox or Moxal and Movicol were suggestive of possible interaction between mebeverine HCl and Rialox or Moxal and Movicol. The intensity of the C=O peak around 2945 cm -1 was reduced for physical mixtures of mebeverine HCl and Rialox or Moxal at a 1:1 ratio, and the peak disappeared for those physical mixtures at a ratio of 1:2.
The previous study showed that mebeverine HCl was absorbed by the magnesium antacid, which likely caused some of the observed decrease in the release of mebeverine HCl in the current study from the various formulations (sugar, film, and retard release tablets) in the presence of the antacids. Antacids can alter drug absorption due to physical adsorption; however, the potential effect of antacids and Movicol on mebeverine HCl absorption could not be assessed in this in vitro study (16, 17) . Despite that, it had been previously suggested that antacids increase the pH of the medium leading to decrease in the dissolution of many antibiotics and the dissolution rate is markedly reduced at high pH values; however, there was no significant increase in pH by the addition of these antacids in the dissolution medium in the current study (17, 18) . Furthermore, differences in the aluminium/magnesium ratios in the tested antacid tablets and suspensions could affect the release of the mebeverine HCl. The types and amounts of excipients or suspending agents added to the antacids and the types and grades of polymers used in the preparation of the suspensions might also affect the viscosity and sedimentation rate in the suspension system.
On the other hand, differences in the form of delivery (sugar-coated tablet, film-coated tablet, or retard release capsule) could account for the observed differences in the release of mebeverine HCl in the system. Clearly, the different dosage forms of a drug can play a role in determining in vitro availability of the drug alone or in combination with other drugs such as antacids. The results (Tables 1) showed that the presence of the salts (Movicol) used to treat constipation, either alone or in combination with the antacids, affected the release rate of the antispasmodic drug (mebeverine HCl). Those results might be due to the effect of sodium chloride on the electrical layer as previously reported and the presence of sodium bicarbonate, which alters the pH. In addition, polyethylene glycol 3350 in the formula of Movicol might affect viscosity (19) .
CONCLUSION
In the present study, the release rate of mebeverine HCl from different formulations was reduced when mebeverine HCl formulations were combined with different antacids and/or Movicol salt. In addition, the results of DSC and IR were also suggestive for interactions between different formulations of mebeverine HCl and antacids and/or Movicol salt. Hence, these interactions might lead to an alteration in the clinical efficacy of mebeverine HCl; therefore, further in vivo studies should be conducted to assess the effect of such interactions on drug absorption and bioavailability.
